Skip to main content
Register
Medicine Matters Rheumatology
TOOLBAR 1 2 3 4
SEARCH
MENU 1 2 3 4
Close search form
main-content
Top
Print
​
print
​
share

13-11-2019 | Rheumatoid arthritis | Video | Article

Researcher comment: The NORD-STAR trial

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).  

Transcript

Back to the ACR/ARP 2019 conference hub

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.

Related content

13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | News

Methotrexate plus glucocorticoids compare favorably with biologics in early RA

31-01-2019 | Rheumatoid arthritis | Highlight | News

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

10-01-2019 | Rheumatoid arthritis | News

Biologic combination therapy for RA may increase risk for side effects

05-11-2019 | Rheumatoid arthritis | Feature | Article

​​​​​​​Treatment tapering in RA: A 2019 update
Why, when, and how should treatment be tapered in people with rheumatoid arthritis?
Image Credits

Version: 0.1602.0